Ascentage Pharma’s MDM2-p53 Inhibitor APG-115 (Alrizomadlin) Granted an Orphan Drug Designation by the FDA for the Treatment of Stage IIB-IV Melanoma, Marking the Twelfth Obtained by the Company

SUZHOU, China and ROCKVILLE, Md., July 21, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused biotechnology company engaged in developing novel therapies for cancers, chronic hep...

Full "IntellAsia: Resources" article